Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $635994.0.

  • InMed Pharmaceuticals' Cost of Revenue fell 227.7% to $635994.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 million, marking a year-over-year increase of 143.45%. This contributed to the annual value of $3.2 million for FY2025, which is 745.74% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Cost of Revenue of $635994.0 as of Q4 2025, which was down 227.7% from $716962.0 recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Cost of Revenue high stood at $1.3 million for Q2 2023, and its period low was $127308.0 during Q1 2022.
  • Moreover, its 5-year median value for Cost of Revenue was $728056.0 (2025), whereas its average is $668484.4.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 56092.78% in 2023, then crashed by 3798.69% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Cost of Revenue stood at $153537.0 in 2021, then surged by 120.55% to $338620.0 in 2022, then soared by 170.53% to $916058.0 in 2023, then fell by 28.96% to $650813.0 in 2024, then dropped by 2.28% to $635994.0 in 2025.
  • Its last three reported values are $635994.0 in Q4 2025, $716962.0 for Q3 2025, and $728056.0 during Q2 2025.